{
  "source": "PA-Notification-Enbrel.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1029-13\nProgram Prior Authorization/Notification\nMedication Enbrel® (etanercept)\nP&T Approval Date 1/2007, 6/2008 , 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 11/2012, 2/2014, 2/2015, 3/2016, 3/2017, 3/2018,\n3/2019, 3/2020, 3/2021, 3/2022, 3/2023, 7/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nEnbrel (etanercept) is a tumor necrosis factor (TNF) blocker indicated for the treatment of\nrheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of\nage or older, psoriatic arthritis (PsA) in patients 2 years of age or older, ankylosing spondylitis\n(AS), and plaque psoriasis (PsO) in patients 4 years or older.1\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\n© 2024 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\nB. Polyarticular Juvenile Idiopathic Arthritis (PJIA)\n1. Initial Authorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic\narthritis\n-AND-\n(2) ",
    "PJIA)\n1. Initial Authorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active polyarticular juvenile idiopathic\narthritis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\nC. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n© 2024 UnitedHealthcare Services, Inc.\n2\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixeki",
    "omodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nD. Plaque Psoriasis\n1. Initial Authorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Diagnosis of chronic moderate to severe plaque psoriasis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n3\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Stelara (ustekinumab), Skyrizi\n(risankizumab), Tremfya (guselkumab), Cosentyx (secukinumab), Taltz\n(ixekizumab), Siliq (brodalumab), Ilumya (tildrakizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla\n(apremilast)]\nAuthorization will be issued for 12 months.\nE. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimuma",
    " ankylosing spondylitis\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Enbrel will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Enbrel therapy\n-AND-\n(2) Patient is not receiving Enbrel in combination with another targeted\nimmunomodulator [e.g., Cimzia (certolizumab), Simponi (golimumab),\nOrencia (abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant\n(baricitinib), Rinvoq (upadacitinib)]\nAuthorization will be issued for12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services, Inc.\n4\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corp.; October 2023.\nProgram Prior Authorization/Notification – Enbrel (etanercept)\nChange Control\n2/2014 Background updated. Concomitant therapy criterion condensed to list\nfour biologic DMARDs and revised to include Xeljanz. Reauthorization\ncriteria revised to standard verbiage and to include concomitant therapy\ncriterion. Extended reauthorization duration to 24 months.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated clinical rules, background and references.\n3/2016 Annual review. Added Otezla (apremilast",
    "n duration to 24 months.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated clinical rules, background and references.\n3/2016 Annual review. Added Otezla (apremilast) to the list of medications\nthat the patient should not be receiving while on Enbrel therapy for\nplaque psoriasis and psoriatic arthritis. Added “polyarticular” to\njuvenile idiopathic arthritis. Updated reference.\n3/2017 Annual review with no change to coverage criteria. Updated\nbackground and references.\n3/2018 Annual review with no change to coverage criteria. Updated\nreferences.\n3/2019 Annual review. Added Olumiant (baricitinib) to list of medications that\npatient should not be receiving while on Enbrel therapy for rheumatoid\narthritis. Updated background.\n3/2020 Annual review. Added Rinvoq (upadacitinib) to list of medications that\npatient should not be receiving while on Enbrel therapy for RA and\nSkyrizi (risankizumab) for PsO. Updated background.\n3/2021 Annual review. Updated reauthorization approval length. Updated\nreference.\n3/2022 Annual review. Updated references.\n3/2023 Annual review. Changed Humira examples to adalimumab and added\nRinvoq as a JAKI example. Added state mandate footnote. Updated\nbackground and reference.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no change to coverage criteria. Updated\nbackground and reference.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}